Comprehending the cuproptosis and cancer-immunity cycle network: delving into the immune landscape and its predictive role in breast cancer immunotherapy responses and clinical endpoints

被引:2
|
作者
Liu, Xiangwei [1 ]
Xu, Feng [2 ]
Zhao, Kunkun [3 ]
Liu, Yunfei [4 ]
Ye, Guolin [1 ]
Zhang, Xin [5 ]
Qu, Yanyu [5 ]
机构
[1] First Peoples Hosp Foshan, Dept Breast Surg, Foshan, Peoples R China
[2] First Peoples Hosp Foshan, Dept Anesthesiol, Foshan, Peoples R China
[3] Foresea Life Insurance Guangzhou Gen Hosp, Dept Breast Surg, Guangzhou, Peoples R China
[4] Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplant Surg, Munich, Germany
[5] Second Peoples Hosp Foshan, Dept Pathol, Foshan, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
BC; cuproptosis; cancer-immunity cycle; immunotherapy response; prognosis; INFILTRATION; PATHOGENESIS; ASSOCIATION; PROGNOSIS;
D O I
10.3389/fimmu.2024.1344023
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background The role of cuproptosis, a phenomenon associated with tumor metabolism and immunological identification, remains underexplored, particularly in relation to the cancer-immunity cycle (CIC) network. This study aims to rigorously examine the impact of the cuproptosis-CIC nexus on immune reactions and prognostic outcomes in patients with breast cancer (BC), striving to establish a comprehensive prognostic model.Methods In the study, we segregated data obtained from TCGA, GEO, and ICGC using CICs retrieved from the TIP database. We constructed a genetic prognostic framework using the LASSO-Cox model, followed by its validation through Cox proportional hazards regression. This framework's validity was further confirmed with data from ICGC and GEO. Explorations of the tumor microenvironment were carried out through the application of ESTIMATE and CIBERSORT algorithms, as well as machine learning techniques, to identify potential treatment strategies. Single-cell sequencing methods were utilized to delineate the spatial distribution of key genes within the various cell types in the tumor milieu. To explore the critical role of the identified CICs, experiments were conducted focusing on cell survival and migration abilities.Results In our research, we identified a set of 4 crucial cuproptosis-CICs that have a profound impact on patient longevity and their response to immunotherapy. By leveraging these identified CICs, we constructed a predictive model that efficiently estimates patient prognoses. Detailed analyses at the single-cell level showed that the significance of CICs. Experimental approaches, including CCK-8, Transwell, and wound healing assays, revealed that the protein HSPA9 restricts the growth and movement of breast cancer cells. Furthermore, our studies using immunofluorescence techniques demonstrated that suppressing HSPA9 leads to a notable increase in ceramide levels.Conclusion This research outlines a network of cuproptosis-CICs and constructs a predictive nomogram. Our model holds great promise for healthcare professionals to personalize treatment approaches for individuals with breast cancer. The work provides insights into the complex relationship between the cuproptosis-CIC network and the cancer immune microenvironment, setting the stage for novel approaches to cancer immunotherapy. By focusing on the essential gene HSPA9 within the cancer-immunity cycle, this strategy has the potential to significantly improve the efficacy of treatments against breast cancer.
引用
收藏
页数:19
相关论文
共 6 条
  • [1] Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer
    Yu, Hao
    Bai, Kexin
    Cheng, Yidong
    Lv, Jiancheng
    Song, Qiang
    Yang, Haiwei
    Lu, Qiang
    Yang, Xiao
    AGING-US, 2023, 15 (13): : 6302 - 6330
  • [2] The complex landscape of breast cancer immune evasion and its implications to personalized and combined immunotherapy
    Bou-Dargham, Mayassa J.
    Liu, Yuhang
    Sang, Qing-Xiang Amy
    Zhang, Jinfeng
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Pan-cancer evaluation of clinical value of mitotic network activity index (MNAI) and its predictive value for immunotherapy
    Mao, Xuanyu
    Cai, Yimeng
    Long, Sarah
    Perez-Losada, Jesus
    Mao, Jian-Hua
    Chang, Hang
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [4] Evaluation of the immune landscape associated with the efficacy of immunotherapy in patients with triple-negative breast cancer: Starlet study, synergy between research and clinical work.
    Gasparini, Elisa
    Ragazzi, Moira
    Manzotti, Gloria
    Torricelli, Federica
    Salviato, Elisa
    Bisagni, Alessandra
    Zanetti, Eleonora
    Pappalardo, Annamaria
    Coiro, Saverio
    Ferrari, Guglielmo
    Soncini, Silvia
    Bisagni, Giancarlo
    Pinto, Carmine
    Ciarrocchi, Alessia
    Reggiani, Francesca
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Results of the window-of-opportunity clinical trial D-BIOMARK: Study of biomarkers of the antitumor activity of denosumab and its role as a modulator of the immune response in early breast cancer
    Vethencourt, A.
    Trinidad, E. M.
    Duch, E. Dorca
    Petit, A.
    Soler-Monso, M. T.
    Purqueras, E.
    Brizzi, M. E.
    Garcia, M. Matas
    Perez-Chacon, G.
    Jimenez, M.
    Ciscar, M.
    Stradella, A.
    Iserte, A.
    Martinez, A. Guma
    Ortega, R.
    Gil, M. J.
    Simon, S. Pernas
    Falo, C.
    Gonzalez-Suarez, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S300 - S300
  • [6] KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy
    Li, Yang
    Lv, Chao
    Yu, Yang
    Wu, Baokang
    Zhang, Yizhou
    Lang, Qi
    Liang, Zhiyun
    Zhong, Chongli
    Shi, Yu
    Han, Shukun
    Xu, Feng
    Tian, Yu
    JOURNAL OF ADVANCED RESEARCH, 2023, 47 : 137 - 150